Fuller & Thaler Asset Management Inc. Sells 18,074 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Fuller & Thaler Asset Management Inc. trimmed its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 1.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,351,880 shares of the specialty pharmaceutical company's stock after selling 18,074 shares during the period. Fuller & Thaler Asset Management Inc. owned about 4.19% of Collegium Pharmaceutical worth $38,731,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently modified their holdings of the business. Price T Rowe Associates Inc. MD grew its position in shares of Collegium Pharmaceutical by 6.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 33,138 shares of the specialty pharmaceutical company's stock valued at $950,000 after purchasing an additional 1,977 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of Collegium Pharmaceutical by 148.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 11,711 shares of the specialty pharmaceutical company's stock worth $336,000 after acquiring an additional 7,000 shares during the period. MetLife Investment Management LLC boosted its stake in Collegium Pharmaceutical by 8.5% in the 4th quarter. MetLife Investment Management LLC now owns 19,987 shares of the specialty pharmaceutical company's stock worth $573,000 after purchasing an additional 1,558 shares during the period. XTX Topco Ltd acquired a new stake in shares of Collegium Pharmaceutical in the 4th quarter valued at about $236,000. Finally, Barclays PLC raised its stake in shares of Collegium Pharmaceutical by 6.3% in the 4th quarter. Barclays PLC now owns 79,754 shares of the specialty pharmaceutical company's stock valued at $2,286,000 after purchasing an additional 4,702 shares during the period.

Insider Activity at Collegium Pharmaceutical

In related news, EVP Scott Dreyer sold 2,255 shares of the company's stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $67,650.00. Following the transaction, the executive vice president now directly owns 124,421 shares in the company, valued at approximately $3,732,630. This represents a 1.78 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Shirley R. Kuhlmann sold 26,067 shares of the business's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $28.50, for a total transaction of $742,909.50. Following the completion of the sale, the executive vice president now directly owns 108,137 shares of the company's stock, valued at $3,081,904.50. This represents a 19.42 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 81,693 shares of company stock worth $2,334,994. Company insiders own 2.51% of the company's stock.

Collegium Pharmaceutical Stock Up 2.8 %

COLL traded up $0.75 during trading on Tuesday, reaching $27.62. 178,967 shares of the stock were exchanged, compared to its average volume of 442,223. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The stock's 50 day moving average price is $28.34 and its two-hundred day moving average price is $30.63. Collegium Pharmaceutical, Inc. has a twelve month low of $23.23 and a twelve month high of $42.29. The stock has a market cap of $887.36 million, a P/E ratio of 11.90 and a beta of 0.76.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping analysts' consensus estimates of $1.54 by $0.09. The business had revenue of $181.95 million during the quarter, compared to analysts' expectations of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. Equities analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. StockNews.com downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday, April 19th. HC Wainwright reiterated a "buy" rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Needham & Company LLC reissued a "buy" rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. Finally, Piper Sandler decreased their target price on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a research report on Tuesday, February 4th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $43.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.